<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82225">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01808248</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-334-0151</org_study_id>
    <nct_id>NCT01808248</nct_id>
  </id_info>
  <brief_title>Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3</brief_title>
  <official_title>A Phase 2, Open-Label Study of Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and antiviral efficacy of
      sofosbuvir (SOF) in combination with Peginterferon Alfa 2a (PEG) and Ribavirin (RBV)
      administered for 12 weeks in participants with chronic genotype 2 or 3 hepatitis C virus
      (HCV) infection who have previously failed prior treatment with an interferon-based regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of treatment (SVR12)</measure>
    <time_frame>Post-treatment Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR12 is defined as HCV RNA &lt; the lower limit of quantitation (LLOQ; ie, &lt; 25 IU/mL) 12 weeks following the last dose of study medication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events leading to permanent discontinuation of study drug(s)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Safety data will be summarized by treatment arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of treatment (SVR4 and SVR24)</measure>
    <time_frame>Post-treatment Weeks 4 and 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR4 and SVR24 is defined as HCV RNA &lt; LLOQ at 4 and 24 weeks following the last dose of study medication, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with virologic failure</measure>
    <time_frame>Baseline to post-treatment Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Virologic failure will be measured by incidence of on-treatment failure and viral relapse.
On-treatment virologic failures
HCV RNA ≥ LLOQ after having previously had HCV RNA &lt;LLOQ while on treatment, confirmed with 2 consecutive values (note: second confirmation value can be posttreatment) or last available on-treatment measurement with no subsequent follow-up values (i.e., breakthrough)
&gt;1 log10 IU/ml increase in HCV RNA from nadir while on treatment, confirmed with 2 consecutive values (note: second confirmation value can be posttreatment) or last available on-treatment measurement with no subsequent follow-up values (i.e., rebound)
HCV RNA persistently ≥LLOQ through 8 weeks of treatment (i.e., non-response)
Relapse
HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA &lt; LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>SOF+PEG+RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SOF+PEG+RBV for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Sofosbuvir (SOF) 400 mg tablet administered orally once daily</description>
    <arm_group_label>SOF+PEG+RBV</arm_group_label>
    <other_name>GS-7977</other_name>
    <other_name>PSI-7977</other_name>
    <other_name>Sovaldi™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG</intervention_name>
    <description>Peginterferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection</description>
    <arm_group_label>SOF+PEG+RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBV</intervention_name>
    <description>Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (&lt; 75kg = 1000 mg and ≥ 75 kg = 1200 mg)</description>
    <arm_group_label>SOF+PEG+RBV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infection with HCV GT 2 or 3

          -  Cirrhosis determination

          -  Subject is treatment-experienced

          -  Screening laboratory values within defined thresholds

          -  Subject has not been treated with any investigational drug or device within 30 days
             of the Screening visit

          -  Use of highly effective contraception methods if female of childbearing potential or
             sexually active male

        Exclusion Criteria:

          -  Prior exposure to an direct-acting antiviral targeting the HCV NS5B polymerase

          -  Pregnant or nursing female or male with pregnant female partner

          -  Current or prior history of clinical hepatic decompensation

          -  History of clinically-significant illness or any other major medical disorder that
             may interfere with subject treatment, assessment or compliance with the protocol

          -  Excessive alcohol ingestion or significant drug abuse
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob Hyland</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alamo Medical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/</url>
    <description>Medicine Plus</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/hepatitis.html</url>
    <description>Hepatitis</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/hepatitisa.html</url>
    <description>Hepatitis A</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/hepatitisc.html</url>
    <description>Hepatitis C</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp</url>
    <description>Drug Information avialble for:</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0036791045&amp;QV1=RIBAVIRIN</url>
    <description>Ribavirin</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0198153514&amp;QV1=PEGINTERFERON+ALFA-2A</url>
    <description>PEGINTERFERON ALFA-2A</description>
  </link>
  <link>
    <url>http://clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>U.S. FDA Resources</description>
  </link>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 17, 2013</lastchanged_date>
  <firstreceived_date>March 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV genotype 2 (GT-2)</keyword>
  <keyword>HCV genotype 3 (GT-3)</keyword>
  <keyword>HCV</keyword>
  <keyword>Sustained Virologic Response</keyword>
  <keyword>Direct Acting Antiviral</keyword>
  <keyword>Combination Therapy</keyword>
  <keyword>Treatment-Naïve</keyword>
  <keyword>GS-7977</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>RBV</keyword>
  <keyword>Peginterferon Alfa 2a</keyword>
  <keyword>PEG</keyword>
  <keyword>Additional relevant MeSH terms:</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>Hepatitis A</keyword>
  <keyword>Hepatitis, Chronic</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Hepatitis C, Chronic</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Hepatitis, Viral, Human</keyword>
  <keyword>Virus Diseases</keyword>
  <keyword>Enterovirus Infections</keyword>
  <keyword>Picornaviridae Infections</keyword>
  <keyword>RNA Virus Infections</keyword>
  <keyword>Flaviviridae Infections</keyword>
  <keyword>Peginterferon alfa-2a</keyword>
  <keyword>Interferon-alpha</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Anti-Infective Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Antimetabolites</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Immunologic Factors</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>Yes</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
    <mesh_term>Physiological Effects of Drugs</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
